<DOC>
	<DOCNO>NCT01726790</DOCNO>
	<brief_summary>To evaluate corneal endothelium cell change intravitreal Bevacizumab injection</brief_summary>
	<brief_title>Effect Intravitreal Bevacizumab Corneal Endothelium</brief_title>
	<detailed_description>Intravitreal Bevacizumab use retinal specialist treatment many retinal disease . Although approved FDA treatment . In many In vitro study , show saftey eye especially corneal endothelium cell , important cell keep cornea clear . This study use Confoscan-Corneal confocal microsope evaluate corneal endothelium intravitreal Bevacizumab injection routine retinal disease 6 month follow .</detailed_description>
	<mesh_term>Corneal Endothelial Cell Loss</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>age 20 80 year old come regular follow 6 month sign write consent form corneal scar , glaucoma history treatment laser antiVEGF therapy 3 month prior recruit high risk cerebrovascular cardiovascular disease Pregnancy breastfeed undergo confocal microspopy History intraocular surgery ocular trauma study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>corneal endothelium</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Intravitreal injection</keyword>
	<keyword>Confoscan</keyword>
</DOC>